AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34865095
Drug: Local oxygen-ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local oxygen-ozone therapy plus medical treatment (n=13)
Trial: 34865095
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment only (Control group, n=12)
Trial: 32705692
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral rifampin (RIF)
Trial: 33121523
Drug: Innovative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative treatments
Trial: 33940662
Drug: Oxa-Gel with
RxNorm normalized name: Q-Gel with Lipoic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxa-Gel with potassium oxalate (PO)
Trial: 33778994
Drug: Peer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer support groups (monthly for the first two months, then every three months for the remainder of the year)
Trial: 36269852
Drug: Ivermectin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin, 400 μg/kg, daily for 3 days (n=817)
Trial: 32628676
Drug: Causal role
RxNorm normalized name: Roledumab
DrugBank: Roledumab (DB16317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Causal role of tyrosine‐protein phosphatase non‐receptor type substrate 1 (SHPS1; SIRPA)
Trial: 35157370
Drug: GDC-0214 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0214 (15 mg twice daily for 14 days)
Trial: 35157370
Drug: 99mTc-radiolabeled GDC-0214
RxNorm normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc-radiolabeled GDC-0214 (1 mg)
Trial: 37797293
Drug: Subcutaneous risankizumab
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous risankizumab 360 mg
Trial: 37797293
Drug: Subcutaneous risankizumab
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous risankizumab 180 mg
Trial: 35644155
Drug: Withdrawal (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal (subcutaneous placebo)
Trial: 32420624
Drug: Initial experimental
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial experimental treatment
Trial: 32420624
Drug: Initial control
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial control treatment
Trial: 34384459
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I), delivered in-person or via telehealth, five weekly sessions.
Trial: 35656654
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of wavelengths 660 and 810 nm
Trial: 34979252
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of TXA intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Trial: 34979252
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Trial: 32947619
Drug: Various therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapies for multiple sclerosis (10 therapies analyzed for relapses)
Trial: 32947619
Drug: Various therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various therapies for multiple sclerosis (7 therapies analyzed for disability progression)
Trial: 32947619
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies except intramuscular interferon beta-1a
Trial: 35975762
Drug: Costoclavicular block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Costoclavicular block (CCB) with 20 ml 0.5% ropivacaine
Trial: 35975762
Drug: Superior trunk
RxNorm normalized name: Sus scrofa superior gastric plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superior trunk block (STB) with 20 ml 0.5% ropivacaine
Trial: 34965006
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract encapsulated chitosan microparticles (GTP) cream
Trial: 35680173
Drug: Combined metabolic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metabolic medication (SINR) containing succinic acid, inosine, nicotinamide, and riboflavin, administered intravenously for 10 days followed by oral administration for 75 days
Trial: 35680173
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered intravenously for 10 days followed by oral administration for 75 days
Trial: 35680173
Drug: Combined metabolic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metabolic medication (SINR)
Trial: 34060685
Drug: Cervical manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical manual therapy plus conventional physiotherapy
Trial: 36122966
Drug: Self‐administered condition‐tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered condition‐tailored psychoeducational intervention
Trial: 36115616
Drug: Single-injection liposomal
RxNorm normalized name: daunorubicin liposomal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection liposomal bupivacaine brachial plexus nerve block (LB)
Trial: 35745210
Drug: Active beetroot
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active beetroot juice (BJ) - 70 mL, 400 mg nitrate
Trial: 35745210
Drug: Placebo beetroot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beetroot juice (BJ) - 70 mL, 0 mg nitrate
Trial: 36454571
Drug: Wearing glasses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearing glasses (e.g., sunglasses) in public spaces for 2 weeks
Trial: 34551181
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) treatment
Trial: 34244212
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of Scavenger Receptor B1 (SCARB1)
Trial: 32012255
Drug: Resection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resection of the end-of-therapy mass
Trial: 33896812
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injection (HAI) with APM
Trial: 33896812
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid injection (HAI) with PT
Trial: 32075993
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMFs); specific details on dosage and duration are not available.
Trial: 32075993
Drug: Placebo; specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; specific details on dosage and duration are not available.
Trial: 36705750
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (SB) supplementation (0.3 g·kg‐1 BM)
Trial: 32167433
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg polyphenols extracted from seeds of red grape (Nero di Troia cultivar) (NATUR‐OX®) for 3 months (T1)
Trial: 33764636
Drug: Sildenafil 25
RxNorm normalized name: sildenafil 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg three times per day plus guideline-recommended treatment for heart failure
Trial: 33764636
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment for heart failure (ACEIs or ARBs, beta-blockers, aldosterone receptor antagonist, digoxin)
Trial: 32618780
Drug: Ozone bagging
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone bagging therapy at 70 μg/mL for 10 minutes every 3 days for 21 days
Trial: 36039391
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil solution
Trial: 36039391
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical spironolactone solution
Trial: 36039391
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil and spironolactone combination
Trial: 32524862
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg two times per day for 5 days
Trial: 34472896
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive remediation therapy (CRT) with 8 group sessions over 2 months
Trial: 35017617
Drug: linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin (5 mg) + insulin
Trial: 35017617
Drug: insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: insulin alone
Trial: 32889844
Drug: Buccal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal DEX gel 0.5 µg/kg
Trial: 32889844
Drug: Buccal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal DEX gel 0.75 µg/kg
Trial: 32889844
Drug: Buccal DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal DEX gel 1 µg/kg
Trial: 34569457
Drug: Tummy time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tummy time >15 minutes daily
Trial: 34569457
Drug: Tummy time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tummy time <15 minutes daily
Trial: 36430138
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL of 1% lidocaine), n = 16
Trial: 32397852
Drug: Topical phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical phenylephrine hydrochloride
Trial: 32397852
Drug: RJ101 (norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RJ101 (norepinephrine releasing agent)
Trial: 33782383
Drug: Open-label stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label stimulation with cognitive behavioural therapy (CBT)
Trial: 32669717
Drug: AAV1/SERCA2a gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV1/SERCA2a gene therapy (1 × 10^13 DNase-resistant particles)
Trial: 32446979
Drug: Xinyue capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinyue capsule (100 mg panax quinquefolius saponins, three times a day)
Trial: 32446979
Drug: Xinyue capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinyue capsule
Trial: 36259542
Drug: Ad26.RSV.preF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF vaccine (1 × 10^11 vp for adults, 5 × 10^10 vp for children)
Trial: 36259542
Drug: Ad26.RSV.preF vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.RSV.preF vaccine
Trial: 33217865
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group
Trial: 35473351
Drug: Time-acupoints-space acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-acupoints-space acupuncture (ATAS) administered weekly
Trial: 33439693
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg IV, day 1) plus carboplatin (AUC 5 mg/mL/min IV, day 1) and etoposide (100 mg/m2 IV, days 1-3)
Trial: 33439693
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus carboplatin (AUC 5 mg/mL/min IV, day 1) and etoposide (100 mg/m2 IV, days 1-3)
Trial: 35848580
Drug: Structured physiotherapy
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured physiotherapy along with conventional treatment
Trial: 36176043
Drug: Low-dose-rate brachytherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose-rate brachytherapy (LDR-BT)
Trial: 36334130
Drug: rHuEPO (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO (20 IU/kg body weight) i.v. injections
Trial: 33515707
Drug: Qizhitongluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qizhitongluo capsule (QZTL)
Trial: 34325540
Drug: Tablets without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets without any bacteria (Control)
Trial: 35397772
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg/day)
Trial: 34339227
Drug: Discontinuing β-lactam
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuing β-lactam treatment after 3 days
Trial: 34339227
Drug: Continuing β-lactam
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing β-lactam treatment for 5 additional days
Trial: 35386854
Drug: Nalbuphine 0.280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.280 mg/kg
Trial: 35386854
Drug: Nalbuphine 0.200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.200 mg/kg
Trial: 35386854
Drug: Nalbuphine 0.140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.140 mg/kg
Trial: 35386854
Drug: Nalbuphine 0.070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.070 mg/kg
Trial: 35386854
Drug: Nalbuphine 0.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.100 mg/kg
Trial: 35898865
Drug: Pulmonary metastasectomy
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary metastasectomy plus standard medical treatment
Trial: 35898865
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment plus possible local ablative measures (e.g., SBRT)
Trial: 33170934
Drug: Azacitidine maintenance
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine maintenance (32 mg/m2 per day subcutaneously for 5 days every 28 days for 12 cycles)
Trial: 32265361
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral etoposide
Trial: 33423518
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of abnormal physiological parameters and warfarin use
Trial: 32788479
Drug: Infusion giving
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion giving set
Trial: 34781708
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg once daily for 2 years)
Trial: 34781708
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg once daily for 2 years)
Trial: 33297730
Drug: Psychoeducational relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational relaxation therapy (PRT, n=84)
Trial: 37149458
Drug: Avelumab maintenance
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab maintenance therapy
Trial: 33512754
Drug: Licogliflozin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licogliflozin (50 mg once daily)
Trial: 32743852
Drug: Antidiabetic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidiabetic drugs
Trial: 33075807
Drug: Kisspeptin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kisspeptin (1 nmol/kg/h intravenous infusion over 75 minutes)
Trial: 33075807
Drug: Vehicle (rate‐matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (rate‐matched infusion)
Trial: 33866916
Drug: Isotretinoin treatment
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin treatment (mean daily dose 38.7 ± 2.8 mg for 7.20 ± 0.79 months)
Trial: 32776169
Drug: Robot-assisted gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-assisted gait training for 2 weeks followed by conventional therapy for 2 weeks
Trial: 32776169
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for 2 weeks followed by robot-assisted gait training for 2 weeks
Trial: 32776169
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy followed by robot-assisted gait training
Trial: 34881844
Drug: Subepithelial connective
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subepithelial connective tissue graft (SCTG) followed by orthodontic treatment
Trial: 34881844
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment only
Trial: 35916932
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention based on the theory of planned behavior (TPB), consisting of six weekly sessions.
Trial: 33976287
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma therapy (two 200 ml transfusions over 24 hours)
Trial: 33377451
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (oral or intravenous) in adults with COVID-19 requiring oxygen or mechanical ventilation
Trial: 33377451
Drug: Alternate equivalent
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate equivalent doses of steroids
Trial: 33377451
Drug: Interleukin-6 inhibitors
RxNorm normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-6 inhibitors (e.g., tocilizumab)
Trial: 33377451
Drug: Empiric antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antimicrobial treatment for likely coinfecting pathogens
Trial: 34587384
Drug: Maintenance group
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance group (continued antidepressant therapy)
Trial: 34587384
Drug: Discontinuation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation group (taper and discontinue therapy with placebo)
Trial: 34587384
Drug: Discontinuation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation group
Trial: 33267539
Drug: Intramuscular injections
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of muramylpeptide composition
Trial: 33267539
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instructions, professional oral hygiene procedures, and root scaling
Trial: 34711479
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g L-Citrulline
Trial: 32645159
Drug: Advanced reproductive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced reproductive age associated with hemoglobin (≥12 vs <12 g/dL)
Trial: 35278844
Drug: IV Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Morphine
Trial: 35101958
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT) preceding IAT
Trial: 33991310
Drug: Nitazoxanide 500
RxNorm normalized name: nitazoxanide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 500 mg BD per oral for 10 days
Trial: 33991310
Drug: Metronidazole 2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 2-2.5 g/day IV for inpatients or 2-2.4 g/day oral for outpatients for 14 days
Trial: 35476706
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic course (13-14 days duration)
Trial: 35476706
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic course (5-6 days duration)